Your browser doesn't support javascript.
loading
Comparison of the efficacy of amisulpride and risperidone in the treatment of patients with first -episode schizophrenia / 中国基层医药
Chinese Journal of Primary Medicine and Pharmacy ; (12): 743-746, 2017.
Artigo em Chinês | WPRIM | ID: wpr-510344
ABSTRACT
Objective To compare and analyze the efficacy and safety of amisulpride and risperidone in the treatment of patients with first -episode schizophrenia(FES).Methods 80 patients with FES were randomly divided into the observation group (n =40,orally given amisulpride)and the control group (n =40,orally given risperidone) according to random number table.The total effective rate,positive and negative symptoms scale (PANSS),adverse reaction rate of two groups were compared.Results 1 week after treatment,the negative symptoms score of the observation group was significantly lower than that of the control group [(20.89 ±3.07 )points vs.(18.15 ± 3.64)points,t =3.639,P =0.001].8 weeks after treatment,the PANSS scores and factor score of the two groups had no significant differences(all P >0.05).The total effective rate and adverse reaction rate of the observation group were 90.00%,17.50% respectively,which of the control group were 82.50%,27.50% respectively,there were no statistically significant differences (χ2 =0.949,P =0.330;χ2 =1.147,P =0.284).Conclusion Amisulpride and risperidone has similar efficacy and safety in the treatment of patients with FES,but amisulpride has better early effect in improving negative symptoms.

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Tipo de estudo: Estudo prognóstico Idioma: Chinês Revista: Chinese Journal of Primary Medicine and Pharmacy Ano de publicação: 2017 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Tipo de estudo: Estudo prognóstico Idioma: Chinês Revista: Chinese Journal of Primary Medicine and Pharmacy Ano de publicação: 2017 Tipo de documento: Artigo